Bispecific IgG antibodies that bind CD3 on T cells and a lymphoma-associated antigen to form an immune synapse, activating T cells to kill tumor cells.
Bispecific IgG antibodies that simultaneously bind CD3 on T cells and a lymphoma-associated antigen on tumor cells, physically bridging the cells to form an immune synapse. This triggers TCR/CD3 signaling, T-cell activation and cytokine release, leading to perforin/granzyme-mediated, MHC-independent lysis of the target tumor cell and serial killing.
The bispecific antibody links CD3 on T cells to CD22 on tumor B cells, forming an immune synapse that activates T cells to release perforin and granzymes, leading to MHC-independent lysis of CD22+ cells.
Small-molecule tyrosine kinase inhibitor targeting BCR-ABL, PDGFR, and c-KIT; exerts antifibrotic effects via PDGF pathway blockade.
ATP-competitive tyrosine kinase inhibitor targeting BCR-ABL, PDGFR, and c-KIT. Blocks downstream signaling (e.g., RAS/MAPK, PI3K/AKT), inhibiting proliferation and promoting apoptosis of kinase-driven cells; also exerts antifibrotic effects via PDGFR pathway blockade.
Imatinib binds the ATP site of the BCR-ABL (ABL1) kinase, blocking its signaling (e.g., RAS/MAPK, PI3K/AKT), which leads to growth arrest and apoptosis of BCR-ABL–dependent leukemia cells.
Monoclonal antibodies linked to cytotoxic payloads that deliver intracellular chemotherapy to antigen-expressing lymphoma cells.
Tumor-targeting monoclonal antibodies linked to a cytotoxic payload bind an antigen on lymphoma cells, internalize, and release the payload intracellularly to damage DNA or microtubules and induce apoptosis, enabling antigen-directed chemotherapy with potential bystander effects.
An anti-CD19 antibody-drug conjugate binds CD19 on tumor cells, is internalized, and releases a cytotoxic payload (e.g., DNA-damaging or microtubule-disrupting agent) inside the cell, causing apoptosis; bystander killing may also occur.
Monoclonal antibodies linked to cytotoxic payloads that deliver intracellular chemotherapy to antigen-expressing lymphoma cells.
Tumor-targeting monoclonal antibodies linked to a cytotoxic payload bind an antigen on lymphoma cells, internalize, and release the payload intracellularly to damage DNA or microtubules and induce apoptosis, enabling antigen-directed chemotherapy with potential bystander effects.
An anti-CD20 antibody–drug conjugate binds CD20 on target cells, is internalized, and releases a cytotoxic payload (e.g., microtubule or DNA-damaging agent) that kills the CD20-expressing cell, with potential bystander effects.
Monoclonal antibodies linked to cytotoxic payloads that deliver intracellular chemotherapy to antigen-expressing lymphoma cells.
Tumor-targeting monoclonal antibodies linked to a cytotoxic payload bind an antigen on lymphoma cells, internalize, and release the payload intracellularly to damage DNA or microtubules and induce apoptosis, enabling antigen-directed chemotherapy with potential bystander effects.
An anti-CD22 ADC binds CD22, is internalized, and releases a cytotoxic payload that damages DNA or microtubules, triggering apoptosis (with possible bystander effect).